射血分数降低心衰住院患者血管紧张素受体脑啡肽酶抑制剂处方模式
ARNI处方率从1.1%升至55.4%,ACEI/ARB从88.3%降至45.9%,任一肾素-血管紧张素系统抑制剂处方率从71.1%升至84.7%。
要点
- ARNI出院处方率7年间从1.1%增至55.4%,但仍有提升空间
- ACEI/ARB处方率同期从88.3%降至45.9%,被ARNI替代
- ACEI、ARB或ARNI任一药物处方率从71.1%升至84.7%
核心结论
- FDA批准沙库巴曲缬沙坦后7年内,HFrEF住院患者出院时ARNI或ACEI/ARB/ARNI处方率增加,ACEI/ARB处方率下降。
- 研究结束时符合条件患者ARNI出院处方率为55.4%,提示仍需持续改进ARNI处方。
研究设计与样本
- 基于Get With The Guidelines-Heart Failure(GWTG-HF)注册的横断面研究,纳入614家参与医院的HFrEF住院患者。
- 按三个时间段评估出院处方率:2015年7月7日至2018年11月10日、2018年11月11日至2021年1月10日、2021年1月11日至2022年12月31日。
- 采用调整logistic回归和分段logistic回归评估发表时间对ARNI处方率的影响。
主要发现
- ARNI出院处方率从2015年7月7日至9月30日的1.1%(27/2451)升至2022年10月1日至12月31日的55.4%(1957/3536)。
- ACEI或ARB出院处方率从88.3%(2612/2957)降至45.9%(2033/4434)。
- ACEI、ARB或ARNI任一药物出院处方率从71.1%(2639/3713)升至84.7%(3990/4711)。
- 与时间段1相比,时间段2和3出院时ARNI处方的调整比值比分别为3.81(95%CI 3.65-3.98)和9.15(95%CI 8.79-9.52)。
- 与时间段1相比,时间段2和3出院时ACEI或ARB处方的调整比值比分别为0.46(95%CI 0.45-0.48)和0.25(95%CI 0.24-0.26)。
临床怎么用
- HFrEF(EF≤40%)住院患者出院时应评估ARNI处方,研究期间处方率虽上升但仍有近半数符合条件患者未使用。
- ACEI/ARB处方率下降与ARNI使用增加相关,临床决策中需根据耐受性和禁忌证选择肾素-血管紧张素系统抑制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Angiotensin receptor-neprilysin inhibition (ARNI) improves mortality among patients with heart failure with reduced ejection fraction (HFrEF), ie, those with an EF of 40% or less. OBJECTIVE: To describe national longitudinal trends in ARNI prescribing patterns among hospitalized patients with HFrEF. DESIGN, SETTING, AND PARTICIPANTS: Using data from the Get With The Guidelines-Heart Failure (GWTG-HF) registry, hospitalized patients with HFrEF at 614 participating hospitals were identified. Rates of ARNI, angiotensin converting enzyme inhibitor (ACEI), and angiotensin II receptor blocker (ARB) prescription at discharge were evaluated across 3 time periods. Adjusted logistic regression and piecewise logistic regression were used to evaluate the impact of publication dates on ARNI prescription rates. EXPOSURES: ARNI prescribing patterns in hospitalized patients with HFrEF. MAIN OUTCOMES AND MEASURES: Rates of ARNI, ACEI, and ARB prescription at discharge were evaluated across 3 time periods as follows: (1) period 1 included the US Food and Drug Administration (FDA) approval of sacubitril-valsartan to the day before the PIONEER-HF (Comparison of Sacubitril-Valsartan vs Enalapril on Effect on N-Terminal Pro-Brain Natriuretic Peptide in Patients Stabilized From an Acute Heart Failure Episode) trial publication (July 7, 2015-November 10, 2018); (2) period 2 included the day of the PIONEER-HF trial publication to the day before publication of the 2021 Update to the 2017 Consensus for Optimization of Heart Failure Treatment (November 11, 2018-January 10, 2021); and (3) period 3 included the day of the 2021 update publication to the last available data at the time of analysis (January 11, 2021-December 31, 2022). RESULTS: A total of 114 333 hospitalized patients (mean [IQR] age, 67.0 [57.0-78.0] years; 74 765 male [65.4%]) were included in this study. Rates of ARNI prescribed at discharge increased from 1.1% (27 of 2451) during July 7, 2015, to September 30, 2015, to 55.4% (1957 of 3536) during October 1, 2022, to December 31, 2022. ACEI or ARB prescription at discharge fell from 88.3% (2612 of 2957) to 45.9% (2033 of 4434) over the same period, whereas ACEI, ARB, or ARNI prescription increased from 71.1% (2639 of 3713) to 84.7% (3990 of 4711). In adjusted logistic regression models, compared with period 1, patients discharged during period 2 and period 3 were found to have a 3.81-fold (95% CI, 3.65-3.98) and 9.15-fold (95% CI, 8.79-9.52) increased odds of ARNI prescription at discharge, and a 0.46 (95% CI, 0.45-0.48) and 0.25 (95% CI, 0.24-0.26) decreased odds of ACEI or ARB prescription at discharge. CONCLUSIONS AND RELEVANCE: Results of this cross-sectional study reveal that in the 7 years after FDA drug approval of sacubitril-valsartan, rates of ARNI or ACEI, ARB, or ARNI prescription at discharge increased, and rates of ACEI or ARB prescription decreased. Overall prescription of ARNI at discharge was 55.4% in eligible patients at the end of the study, suggesting remaining opportunity for continued improvement in ARNI prescription.
引用
- Srivastava, Klomhaus, Greene, et al. Angiotensin Receptor-Neprilysin Inhibitor Prescribing Patterns in Patients Hospitalized for Heart Failure. JAMA Cardiol. 2025. PMID: 39661383. doi:10.1001/jamacardio.2024.3815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。